Abstract:Racial and ethnic inequities in the receipt of medications to treat opioid use disorder (MOUD) have been well described. Ross and colleagues 1 provide an important addition to the existing literature on MOUD disparities, identifying racial differences in buprenorphine and methadone dosing across 3 trials completed within the National Institute on Drug Abuse Clinical Trials Network (CTN). Similar to prior research, Ross and colleagues 1 found a significant difference among methadone dosing among Non-Hispanic Black compared with Non-Hispanic White participants in their fully adjusted models. 2 Additionally, Ross and colleagues 1 describes differences in mean buprenorphine dosing and the proportion of participants receiving high buprenorphine or methadone doses among Non-Hispanic Black compared with Non-Hispanic White participants. Dosing disparities are particularly concerning because higher MOUD doses have been associated with greater retention in treatment. 3 While the differences identified were not significant after covariate adjustment (sex, age, withdrawal symptom severity, comorbid conditions, and drug use history), overadjustment and small sample sizes, particularly for the Non-Hispanic Black and Hispanic participants, may have limited the findings. The findings of Ross et al 1 must be understood in the context of the national randomized clinical trials whose data they analyzed. The first trial, the START trial (2006-2010), compared buprenorphine-naloxone and methadone in patients with opioid use disorder (OUD) with a primary outcome of liver function at 6 months (CTN-0027). Of note, a larger percentage of White participants who gave consent were screened out prior to randomization (75% vs 64%). 4 The second trial (2006-2009), the POATS study (CTN-0030 Phase 2), evaluated various doses of buprenorphine-naloxone with and without counseling for individuals with prescription opioid dependence, with a primary outcome of abstinence from nonprescribed opioids. Of note, this trial had the lowest rate of Non-Hispanic Black and Hispanic participants (7.5% compared with 27% in CTN-0027 and 30% in CTN-0051). Finally, the third trial, the X:BOT study (2014-2016), compared the effectiveness of intramuscular naltrexone vs buprenorphine-naloxone (CTN-0051). The first 2 trials took place prior to the introduction of fentanyl in the drug supply, with its emergence overlapping with CTN-0051. The Ross et al 1 secondary analysis pooled heterogeneous data on buprenorphine and methadone dosing and evaluated differences by race and ethnicity during the first 4 weeks of treatment. All studies included randomized treatment assignment and participants were from sites across the country. Each trial protocol provided similar dosing recommendations and allowed clinicians the flexibility to make adjustments based on clinical or subjective opioid withdrawal scores and clinical judgment. For a patient initiating methadone or burprenorphine to stabilize, a number of steps are necessary. First, they need to be assessed for, and diagnosed with, OUD. Then, they need access to a clinician who can prescribe MOUD or admission to an opioid treatment program, both of which require overcoming stigma, insurance, and transportation-related barriers. If the patient receives buprenorphine, certain insurance plans require prior authorizations for higher doses, mandate behavioral treatment attendance, or require frequent urine drug testing. 5 These barriers can be factors in stigma against addiction and may require additional clinical resources, which limits timely access to medications. For individuals receiving methadone, they typically must attend a specialized clinic daily and receive their medications under supervision. These clinics are only available in certain geographic areas and are often concentrated in high-poverty neighborhoods. Once a medication has been initiated, identifying stabilization with the right dose often requires frequent dose adjustments over several weeks. Finally, individuals must continue to take the medication as prescribed, attend follow-up visits, and meet treatment program requirements. Each step is subject to individual biases from clinicians, stigma against addiction, and structural racism in and outside of the health care setting–hindering progression along the OUD cascade of care. Policies within health care organizations, as well as state and national restrictive opioid-related policies, have had a negative impact in patient access to care and retention in care, especially for Black patients. While the clinical trial setting removes many barriers to medication access early in this pathway once enrolled, disparities in trial enrollment by race can affect the generalizability of the findings and limit confidence in the effectiveness of new treatments in clinical settings whe -Abstract Truncated-

Association between buprenorphine capacity rates and percentages of ethnic/racial minorities at the county level in the United States

Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine

Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study

Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA

Racial Inequality in Receipt of Medications for Opioid Use Disorder

Buprenorphine Receipt and Retention for Opioid Use Disorder following an Initiative to Increase Access in Primary Care

Buprenorphine Use Among Non-Hospital Residential Programs

Variability in Practice of Buprenorphine Treatment by Emergency Department Operational Characteristics

Racialized environments and syringe services program implementation: County-level factors

The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints

Examining Racial/Ethnic Differences in Patterns of Opioid Prescribing: Results from an Urban Safety-Net Healthcare System

Association between high-threshold practices and buprenorphine treatment termination

Dosing Inequities in Opioid Use Disorder Treatment Trials

There goes the neighborhood? The public safety enhancing effects of a mobile harm reduction intervention

"You Do More Difficult Things Than This": A National Study of Nurse Practitioner Buprenorphine Prescribing

County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities

Emergency Department Access to Buprenorphine for Opioid Use Disorder

Opening the "black box": Four common implementation strategies for expanding the use of medications for opioid use disorder in primary care

Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018

Buprenorphine prescribing practices for older adults in 2019 and 2020

Differences by race and ethnicity in drug use patterns, harm reduction practices and barriers to treatment among people who use drugs in Rhode Island